NYVEPRIA is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is Pegfilgrastim.
Product ID | 0069-0324_1995cf41-7843-4402-a82b-c093f249c016 |
NDC | 0069-0324 |
Product Type | Human Prescription Drug |
Proprietary Name | NYVEPRIA |
Generic Name | Pegfilgrastim-apgf |
Dosage Form | Injection, Solution |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2020-12-15 |
Marketing Category | BLA / BLA |
Application Number | BLA761111 |
Labeler Name | Pfizer Laboratories Div Pfizer Inc |
Substance Name | PEGFILGRASTIM |
Active Ingredient Strength | 6 mg/.6mL |
Pharm Classes | Granulocyte Colony-Stimulating Factor [CS],Granulocyte-Macrophage Colony-Stimulating Factor [CS],Increased Myeloid Cell Production [PE],Leukocyte Growth Factor [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2020-12-15 |
NDC Exclude Flag | N |
Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
NYVEPRIA 88693853 not registered Live/Pending |
Hospira, Inc. 2019-11-15 |
NYVEPRIA 87261611 not registered Live/Pending |
Hospira, Inc. 2016-12-08 |